Novel oligonucleotides data presented at Options Conference

Key points

• Novel oligonucleotides data presented at Options XIII Conference
• Results show promise in reducing vaccine-related inflammation
• Versatile technology attracting attention from biotech companies

Full summary

Noxopharm Limited, an Australian biotech company, presented promising data on its novel oligonucleotides technology at the Options XIII Conference, the largest global scientific meeting focused on influenza. The research, conducted in collaboration with CSL, aimed to explore how Noxopharm's oligonucleotides could improve the reactogenicity of self-amplifying mRNA vaccines. The results indicated that Noxopharm's oligos showed clear promise in reducing vaccine-related inflammation markers, confirming their potential in improving vaccine tolerability. CEO Dr. Olivier Laczka highlighted the versatility of the technology and its potential to play a key role in the rapidly growing mRNA vaccine market.